A Non-Surgical 24-Hour Continuous Levodopa Infusion for Advanced Parkinson's Disease

October 14, 2025

Tuesday, October 14, 2025 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Parkinson’s disease is a neurodegenerative disorder characterized by the dysfunction and loss of dopamine-producing neurons in the brain, along with the accumulation of Lewy body pathology1. The condition leads to a gradual progression of both motor and non-motor symptoms. Although oral dopaminergic drugs provide symptom control for about 3 to 6 years, their benefits decrease over time, resulting in a narrower therapeutic window and worsening symptoms. Within 5 to 10 years, many patients develop advanced Parkinson’s Disease, facing increased complications, greater disability from standard drug therapies, and significant impacts on quality of life and daily functioning2.

Vyalev (Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion) offers the first 24-hour subcutaneous infusion of levodopa-based treatment, specifically designed to help individuals with advanced Parkinson’s Disease experiencing severe motor fluctuations not adequately managed by other therapies.

References:

  • Kouli A, et al. 2018. Parkinson's Disease: Pathogenesis and Clinical Aspects [Book]. Brisbane (AU): Codon Publications; Chapter 1.
  • Varanese S, et al. 2011. Parkinson’s Disease. 480260.
  • Chaudhuri KR, et al. 2024.  Drugs Real World Outcomes. 11(1):1-11.
  • VYALEV™ [package insert]. 2024. North Chicago, IL: AbbVie.

Learning Objectives

  • Describe the 24-hour burden of Parkinson's disease and diminished treatment response in advanced stages of disease.
  • Discuss the clinical trial of a continuous subcutaneous 24-hour levodopa infusion for people with advanced Parkinson's disease.
  • Explore real-world patient and clinician experiences with Parkinson's disease and the evolving treatment paradigm.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.

Course summary
Course opens: 
09/21/2025
Course expires: 
10/14/2025
Event starts: 
10/14/2025 - 2:00pm EDT
Event ends: 
10/14/2025 - 3:00pm EDT
Cost:
$0.00
Add to calendar: 

Speaker:

Michael J. Soileau, MD, FAAN
Founder and Clinician
Texas Movement Disorder Specialists

Price

Cost:
$0.00
Please login or register to take this course.

By registering for this event, you agree not to use any form of artificial intelligence (AI) technology to record, transcribe, or reproduce educational sessions, presentations, or discussions in any format.

Click here for more information on AMCP membership or email memberservices@amcp.org.

Required Hardware/software

AMCP Learn utilizes the Zoom Webinars platform for live webinars. For a smoother experience joining the webinar, please install the Zoom desktop client or mobile app prior to the start time. If you experience technical issues joining the webinar, please email webinars@amcp.org.